JP6096111B2 - 免疫刺激組成物及びワクチン組成物 - Google Patents

免疫刺激組成物及びワクチン組成物 Download PDF

Info

Publication number
JP6096111B2
JP6096111B2 JP2013509404A JP2013509404A JP6096111B2 JP 6096111 B2 JP6096111 B2 JP 6096111B2 JP 2013509404 A JP2013509404 A JP 2013509404A JP 2013509404 A JP2013509404 A JP 2013509404A JP 6096111 B2 JP6096111 B2 JP 6096111B2
Authority
JP
Japan
Prior art keywords
mannan
antigen
composition
kda
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013509404A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013527854A5 (https=
JP2013527854A (ja
Inventor
ジェフリー・アラン・ピーターズ
Original Assignee
アセンド・バイオファーマシューティカルズ・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2010901997A external-priority patent/AU2010901997A0/en
Application filed by アセンド・バイオファーマシューティカルズ・リミテッド filed Critical アセンド・バイオファーマシューティカルズ・リミテッド
Publication of JP2013527854A publication Critical patent/JP2013527854A/ja
Publication of JP2013527854A5 publication Critical patent/JP2013527854A5/ja
Application granted granted Critical
Publication of JP6096111B2 publication Critical patent/JP6096111B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55583Polysaccharides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2013509404A 2010-05-10 2011-05-10 免疫刺激組成物及びワクチン組成物 Expired - Fee Related JP6096111B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US33308610P 2010-05-10 2010-05-10
US61/333,086 2010-05-10
AU2010901997 2010-05-10
AU2010901997A AU2010901997A0 (en) 2010-05-10 Immunostimulatory and vaccine compositions
AU2010904060A AU2010904060A0 (en) 2010-09-09 Immunostimulatory and vaccine compositions
AU2010904060 2010-09-09
PCT/AU2011/000542 WO2011140595A2 (en) 2010-05-10 2011-05-10 Immunostimulatory and vaccine compositions

Publications (3)

Publication Number Publication Date
JP2013527854A JP2013527854A (ja) 2013-07-04
JP2013527854A5 JP2013527854A5 (https=) 2014-06-26
JP6096111B2 true JP6096111B2 (ja) 2017-03-15

Family

ID=44914748

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013509404A Expired - Fee Related JP6096111B2 (ja) 2010-05-10 2011-05-10 免疫刺激組成物及びワクチン組成物

Country Status (9)

Country Link
US (1) US9597392B2 (https=)
EP (1) EP2574170A4 (https=)
JP (1) JP6096111B2 (https=)
CN (1) CN102985095B (https=)
AU (1) AU2011226992B2 (https=)
BR (1) BR112012028893A2 (https=)
CA (1) CA2798856C (https=)
RU (1) RU2578420C2 (https=)
WO (1) WO2011140595A2 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2170384T3 (en) 2007-07-02 2016-07-25 Etubics Corp METHODS AND COMPOSITIONS FOR THE PRODUCTION OF AN adenovirus vector for use in higher vaccination
AU2012334825B2 (en) * 2011-11-09 2017-08-24 Ascend Biopharmaceuticals Ltd Immunomodulatory conjugates
US9605276B2 (en) 2012-08-24 2017-03-28 Etubics Corporation Replication defective adenovirus vector in vaccination
ES2503516B1 (es) * 2013-04-03 2015-09-09 Inmunotek, S.L. Complejo inmunogénico para vacunación y método de obtención
CN107406857B (zh) 2015-01-09 2021-06-29 埃图比克斯公司 用于联合免疫治疗的方法和组合物
AU2016205208A1 (en) 2015-01-09 2017-07-06 Etubics Corporation Methods and compositions for ebola virus vaccination
US11149087B2 (en) 2015-04-20 2021-10-19 Etubics Corporation Methods and compositions for combination immunotherapy
WO2018005226A2 (en) 2016-06-22 2018-01-04 Alkermes, Inc. Compositions and methods for modulating il-10 immunostimulatory and anti-inflammatory properties
US11116808B2 (en) 2018-08-06 2021-09-14 Nielsen Biosciences, Inc. Treatment of warts
US11197910B1 (en) * 2020-08-19 2021-12-14 Vitruviae LLC Fusion proteins for the diagnosis, prophylaxis and treatment of infectious diseases
AU2022234358A1 (en) * 2021-03-12 2023-10-19 Children's Medical Center Corporation Polysaccharide adjuvants for virus vaccines
CN113616799B (zh) * 2021-07-13 2023-08-29 中国科学院长春应用化学研究所 一种疫苗载体、其制备方法及应用
JPWO2024117232A1 (https=) * 2022-11-30 2024-06-06

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3362951A (en) 1965-12-21 1968-01-09 Farkas Alexander Polysaccharide product derived from the juice of the aloe plant and methods for preparing same
US4735935A (en) 1985-12-17 1988-04-05 Carrington Laboratories, Inc. Process for preparation of aloe products products, produced thereby and compositions thereof
US5308838A (en) 1982-05-07 1994-05-03 Carrington Laboratories, Inc. Uses of aloe products
US4861761A (en) 1984-06-28 1989-08-29 Dr. Madis Laboratories, Inc. Aloeferon isolation, manufacturing and its applications
FR2573656B1 (fr) * 1984-11-29 1987-02-27 Sanofi Sa Medicament comportant en tant qu'association au moins une immunotoxine et au moins un polymere contenant du mannose
US6054438A (en) 1987-01-07 2000-04-25 Imperial Cancer Research Technology Limited Nucleic acid fragments encoding portions of the core protein of the human mammary epithelial mucin
CA1339204C (en) 1987-01-07 1997-08-05 Joyce Taylor-Papadimitriou Mucin core polypeptide, antibodies and probes
US5643578A (en) 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
US5744144A (en) 1993-07-30 1998-04-28 University Of Pittsburgh University Patent Committee Policy And Procedures Synthetic multiple tandem repeat mucin and mucin-like peptides, and uses thereof
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
ATE475668T1 (de) 1994-01-27 2010-08-15 Univ Massachusetts Medical Immunisierung durch impfung von dns transkriptionseinheit
US5939400A (en) 1996-02-26 1999-08-17 The Board Of Trustees Of The Leland Stanford Junior University DNA vaccination for induction of suppressive T cell response
WO1997044446A1 (en) 1996-05-24 1997-11-27 University Of Maryland At Baltimore Dna vaccines for eliciting a mucosal immune response
US5824659A (en) 1996-09-04 1998-10-20 Board Of Regents, The University Of Texas System Cytoprotective oligosaccharide from Aloe preventing damage to the skin immune system by UV radiation
ATE341339T1 (de) 1996-12-20 2006-10-15 Merck & Co Inc Zusammensetzungen von rekombinanten papillomavirus vakzinen
CA2289742C (en) 1997-05-08 2013-07-16 Biomira Inc. Method for generating activated t-cells and antigen-pulsed antigen-presenting cells
US6573245B1 (en) 1998-04-28 2003-06-03 Galenica Pharmaceuticals, Inc. Modified polysaccharide adjuvant-protein antigen conjugates, the preparation thereof and the use thereof
IL125608A0 (en) 1998-07-30 1999-03-12 Yeda Res & Dev Tumor associated antigen peptides and use of same as anti-tumor vaccines
DE19917195B4 (de) 1999-04-16 2006-09-28 Immatics Biotechnologies Gmbh Peptid zur Auslösung einer Immunreaktion gegen Tumorzellen, diese enthaltende pharmzeutische Zusammensetzungen, dessen Verwendungen, dafür codierende Nukleinsäure und diese Nukleinsäure enthaltender Expressionsvektor
CA2383737C (en) 1999-09-08 2011-01-18 Transgene S.A. Muc-1 derived peptides
JP2003533181A (ja) 2000-02-01 2003-11-11 ジ・オースティン・リサーチ・インスティテュート ムチン−1誘導抗原および免疫療法におけるその使用
AUPQ797700A0 (en) 2000-06-06 2000-06-29 Austin Research Institute, The Vaccine
WO2008037033A1 (en) * 2006-09-29 2008-04-03 The Macfarlane Burnet Institute For Medical Research And Public Health Limited Flu vaccine admixture of mannan and flu antigen
WO2002003999A1 (en) * 2000-07-10 2002-01-17 The University Of Missisippi High molecular weight polysaccharide fraction from aloe vera with immunostimulatory activity
JP2004505925A (ja) * 2000-08-10 2004-02-26 オーシャン、ニュートリッション、カナダ、リミテッド 免疫調節特性を示すクロレラ調製物
DK1545597T3 (da) 2002-08-15 2011-01-31 3M Innovative Properties Co Immunstimulerende sammensætninger og fremgangsmåde til stimulering af en immunrespons
EP2181595A1 (en) 2002-08-16 2010-05-05 Yeda Research And Development Company Ltd. Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines
WO2005044861A1 (en) * 2003-10-31 2005-05-19 Wyeth Holdings Corporation Polysaccharides of helicobacter pylori
WO2005047507A1 (en) * 2003-11-12 2005-05-26 The Austin Research Institute Dna-carrier conjugate
US20060084629A1 (en) 2004-10-15 2006-04-20 Alvin Needleman Immune system activating formula composed of selected long chain polysaccharides from natural sources
JP2006241023A (ja) * 2005-03-01 2006-09-14 Asahi Breweries Ltd 消化管組織における抗菌ペプチドの発現誘導または産生促進剤
JP2006241020A (ja) * 2005-03-01 2006-09-14 Asahi Breweries Ltd 免疫系賦活剤
EP1988896A4 (en) 2006-02-22 2011-07-27 3M Innovative Properties Co CONJUGATES TO MODIFY IMMUNE REACTIONS
CA2648099C (en) 2006-03-31 2012-05-29 The Brigham And Women's Hospital, Inc System for targeted delivery of therapeutic agents
US20090317414A1 (en) 2006-07-25 2009-12-24 4G Vaccines Pty Ltd Cancer vaccine comprising a mucin 1 (muc1) t cell epitope-derived peptide
WO2008039432A1 (en) 2006-09-26 2008-04-03 Alexion Pharmaceuticals, Inc. Compositions and methods for enhancing an adjuvant
US20080149123A1 (en) 2006-12-22 2008-06-26 Mckay William D Particulate material dispensing hairbrush with combination bristles

Also Published As

Publication number Publication date
WO2011140595A2 (en) 2011-11-17
EP2574170A4 (en) 2013-11-20
BR112012028893A2 (pt) 2017-12-12
RU2578420C2 (ru) 2016-03-27
JP2013527854A (ja) 2013-07-04
AU2011226992B2 (en) 2012-03-22
CA2798856C (en) 2019-04-23
RU2012152952A (ru) 2014-06-20
WO2011140595A3 (en) 2012-01-05
US20130251741A1 (en) 2013-09-26
US9597392B2 (en) 2017-03-21
EP2574170A2 (en) 2013-04-03
CA2798856A1 (en) 2011-11-17
AU2011226992A1 (en) 2011-11-24
CN102985095B (zh) 2016-05-18
CN102985095A (zh) 2013-03-20

Similar Documents

Publication Publication Date Title
JP6096111B2 (ja) 免疫刺激組成物及びワクチン組成物
JP6916231B2 (ja) 新生物ワクチン用製剤
US10344261B2 (en) Immunomodulatory conjugates
JP2021152053A (ja) 新生物ワクチン用の製剤及びその製剤を調製する方法
HK1215052A1 (zh) 一种核苷酸疫苗
JP2017538672A (ja) Cmv由来改変ウイルス様粒子
US11638753B2 (en) Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy
US12478669B1 (en) Herpes zoster mRNA vaccine, preparation method therefor, and use thereof
JP2024036364A (ja) I型インターフェロン遺伝子を刺激するための方法及びカチオン性脂質を含む組成物
JP6165182B2 (ja) 免疫アジュバントとしてのグリコシル化により改変された四官能性非イオン性両親媒性ブロックコポリマーの使用
US20060286115A1 (en) Preventive cancer vaccine based on brother of regulator of imprinted sites molecule
Ji et al. A novel rapid modularized hepatitis B core virus-like particle-based platform for personalized cancer vaccine preparation via fixed-point coupling
JP2005526520A (ja) Vntr反復ユニットの数が減少したmuc−1抗原
AU2012200183B2 (en) Immunostimulatory and vaccine compositions
JP2022036961A (ja) 樹状細胞療法においてex vivoでの抗原のプロセシングと提示を亢進させるための合成ベクターとしての脂質
TWI916817B (zh) 一種針對MICA/B靶點的mRNA腫瘤疫苗
WO2008151389A1 (en) Chemically modified macromolecules
US20230414763A1 (en) Transmucosal amphiphile-protein conjugate vaccine
US8921534B2 (en) Enhancement of the immune response using CD36-binding domain
WO2024222886A1 (zh) 一种针对MICA/B靶点的mRNA肿瘤疫苗
CN121759480A (zh) 一种关联人巨细胞病毒被膜磷蛋白65的组合物及其制备方法和应用
WO2026034613A1 (ja) mRNAワクチンアジュバント
WO2023013785A1 (ja) Snareを活用した核酸構築物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140508

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140508

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150608

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150908

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160506

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160801

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161201

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20161228

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170123

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170215

R150 Certificate of patent or registration of utility model

Ref document number: 6096111

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees